Lymphoma Clinical Trial
Official title:
Preemptive Ethanol Lock Therapy in Pediatric Hematology/Oncology Patients With Catheter Associated Bloodstream Infection: Impact on Length of Stay and Catheter Salvage
NCT number | NCT02095951 |
Other study ID # | 2024.11 |
Secondary ID | |
Status | Completed |
Phase | Phase 4 |
First received | |
Last updated | |
Start date | June 2014 |
Est. completion date | June 2016 |
Verified date | August 2018 |
Source | Children's Hospital of Michigan |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study team will compare hospital length of stay (LOS) and attributable length of stay
(ALOS, the LOS attributable to CRI), in a randomized, un-blinded prospective trial utilizing
short-dwell ethanol-lock therapy (ELT) (4 hours to 24 hour dwell times per day, repeated for
up to 72 hours) placed within 24 - 36 hours of admission(Group 1, Preemptive ELT) versus ELT
placed at the time of first positive blood culture report (Group 2, Rescue ELT (Standard of
Care ). ELT will be given in both groups, in combination with systemic antibiotics, for the
treatment of CRI (suspected or proven) of the blood in children with central catheters.
Participants will be enrolled from patients with hematologic/oncologic disorders and bone
marrow or hematopoetic stem cell transplants (BMT) admitted for care to Children's Hospital
of Michigan (CHM), a tertiary care pediatric hospital in Detroit, Michigan. ALOS will be
defined as the number of hospital days between first symptoms of Catheter-related infection
(CRI) (or date of admission for those admitted with symptoms) and first negative blood
culture.
Study Hypothesis: The main hypothesis is that the short-dwell ethanol-lock therapy, defined
above, placed within 24 - 36 hours of symptoms/admission (Arm 1) versus ELT placement at the
time of first positive blood culture report (Arm 2), with concomitant systemic antibiotics,
for the treatment of CRI (suspected or proven) of the blood in children with central
catheters in the H/O/BMT population will have shorter hospital length of stay (LOS) and
attributable LOS (ALOS) and therefore lower hospital costs.
Status | Completed |
Enrollment | 30 |
Est. completion date | June 2016 |
Est. primary completion date | June 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Months to 21 Years |
Eligibility |
Inclusion Criteria: - All children up to 21 years of age, with central catheters (any type) that develop symptoms and are admitted to CHM with an underlying H/O/BMT diagnosis for individual episodes of suspected or proven CRI of the blood, including rule out sepsis, will be screened for potential participation in this study. - Individual CRI episodes in the same patient will be defined as a distinct central catheter associated blood stream infection if separated by greater than 28 days from prior ELT procedure and caused by a different organism identified on culture than the prior central catheter associated blood stream infection episode. - Participants meeting study enrollment criteria will be offered participation and must have parental full informed consent, adolescent assent and young child verbal assent prior to enrollment as applicable. Exclusion Criteria: - Children with documented allergy to ethanol or alcohol will be excluded. Blood cultures from patients that are reported positive for pathogen growth within 12 hours from the time they are obtained will be excluded from the study. - Any patient at CHM with an infected central catheter and with another indwelling foreign body that communicates directly with the bloodstream, of which infection or colonization could not be excluded directly, will also be excluded from the study (i.e. Left Ventricular Assist Device) as it will not be possible to assess sterilization of the central catheter. - Any patient with endocarditis or presumed endovascular infection will also be excluded. - Any patient deemed critically ill or unstable, upon admission or during the early treatment course, in which case the treating clinician(s) feel that immediate line removal is potentially life-saving will be excluded from the study. |
Country | Name | City | State |
---|---|---|---|
United States | Children's Hospital of Michigan | Detroit | Michigan |
Lead Sponsor | Collaborator |
---|---|
Children's Hospital of Michigan | Blue Cross Blue Shield of Michigan Foundation |
United States,
Chaudhary M, Bilal MF, Du W, Chu R, Rajpurkar M, McGrath EJ. The impact of ethanol lock therapy on length of stay and catheter salvage in pediatric catheter-associated bloodstream infection. Clin Pediatr (Phila). 2014 Oct;53(11):1069-76. doi: 10.1177/0009922814533591. Epub 2014 May 7. — View Citation
McGrath E, Du W, Rajpurkar M. Preemptive Ethanol Lock Therapy in Pediatric Hematology/Oncology Patients With Catheter-Associated Bloodstream Infection: Impact on Length of Stay, Cost, and Catheter Salvage. Clin Pediatr (Phila). 2018 Mar;57(3):285-293. doi — View Citation
McGrath EJ, Salloum R, Chen X, Jiang Y, Boldt-MacDonald K, Becker C, Chu R, Ang JY. Short-dwell ethanol lock therapy in children is associated with increased clearance of central line-associated bloodstream infections. Clin Pediatr (Phila). 2011 Oct;50(10):943-51. doi: 10.1177/0009922811409568. Epub 2011 May 27. — View Citation
Rajpurkar M, McGrath E, Joyce J, Boldt-MacDonald K, Chitlur M, Lusher J. Therapeutic and prophylactic ethanol lock therapy in patients with bleeding disorders. Haemophilia. 2014 Jan;20(1):52-7. doi: 10.1111/hae.12241. Epub 2013 Aug 1. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Length of Stay (LOS) in Those With 14 Confirmed Catheter Related Infection Cases | A primary endpoint of this study is length of stay (LOS) per catheter infection episode/admission | Participants will be followed for the duration of hospital stay, an expected average of 2 weeks | |
Primary | Attributable Length of Stay (ALOS) in 14 Confirmed Catheter Related Infection Cases | TIME FROM FIRST POSITIVE TO FIRST NEGATIVE BLOOD CULTURE | Participants will be followed for the duration of hospital stay, an expected average of 2 weeks | |
Primary | Hospital COSTS in 14 Confirmed Catheter Related Infection Cases | Hospital COSTS | Participants will be followed for the duration of hospital stay, an expected average of 2 weeks | |
Secondary | Catheter Sterilization | Number of Catheters sterilized with interventions | Participants will be followed for the duration of hospital stay, an expected average of 2 weeks | |
Secondary | Catheter Salvage | Number of Infected catheters (which achieved sterilization) with salvage for at least 14 days. | Participants will be followed for the duration of hospital stay, an expected average of 2 weeks | |
Secondary | Number of Adverse Events Per Episode of Catheter Infection | Number of Adverse events per episode of distinct catheter infection that are thought to be related to the actual study intervention, namely timing of ethanol lock placement, will be reviewed and reported for each individual infection episode/admission. | Participants will be followed for the duration of hospital stay, an expected average of 2 weeks but up to 1 month post the last ethanol dose administration | |
Secondary | Re-infection | Number of Re-Infected of salvaged catheters with same or new organism(s) within 28 days of prior CRI/ELT | Participants will be followed for the duration of hospital stay, an expected average of 2 weeks but for up to 1 month total |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540340 -
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
|
Phase 1 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT00001512 -
Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Completed |
NCT01410630 -
FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
|
||
Active, not recruiting |
NCT04270266 -
Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT01949883 -
A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma
|
Phase 1 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Recruiting |
NCT05019976 -
Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma
|
N/A | |
Completed |
NCT04434937 -
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)
|
Phase 2 | |
Completed |
NCT01855750 -
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
|
Phase 3 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT00775268 -
18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03936465 -
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
|
Phase 1 |